<ul>
<li><em>该专利涉及向女性性功能障碍患者施用有效剂量的孤立同种异体间充质干细胞（MSCs）的方法，以提高其性生活质量</em></li>
<li><em>女性性功能障碍是一种极为常见的未满足医疗需求，可能对健康女性的生活质量产生重大影响</em></li>
<li><em>Longeveron 预计将签订许可或合作协议，以开发和商业化针对该适应症的干细胞疗法</em></li>
</ul>
<p>迈阿密，2025 年 12 月 17 日（GLOBE NEWSWIRE）-- Longeveron Inc.（纳斯达克：LGVN），一家开发针对危及生命的罕见儿科和慢性衰老相关疾病的细胞疗法的临床阶段生物技术公司，今天宣布美国专利商标局（USPTO）已授予一项专利，涵盖该公司专有的间充质干细胞（MSCs）用于治疗女性性功能障碍及改善性生活质量的管理。</p>
<p>美国专利号 12,496,316，标题为 “性功能障碍的治疗及性生活质量的改善”，为 Longeveron 提供了至 2038 年的美国专利权。进一步的专利期限延长可能会与监管独占权延长一起发生。</p>
<p>女性性功能障碍是一种极为常见但研究不足的问题，影响多达 46% 的女性，治疗选择寥寥无几。重要的是，女性性功能障碍在年龄增长时愈加普遍，影响健康个体。该专利增加了 Longeveron 日益增长的与优先影响老年人群体相关的疾病的专利组合。</p>
<p>Longeveron 预计将签订许可或合作协议，以开发和商业化针对该适应症的干细胞疗法。</p>
<p><strong>关于 laromestrocel (LOMECEL-B®)</strong></p>
<p>Laromestrocel 是一种活细胞产品，由从年轻健康成人捐赠者的骨髓中分离的专门细胞制成。这些专门细胞被称为间充质干细胞（MSCs），对我们内源性生物修复机制至关重要。研究表明，MSCs 在体内执行多种复杂功能，包括新组织的形成。它们还被证明能够响应损伤或疾病的部位，并分泌具有免疫调节和再生作用的生物活性因子。我们相信，laromestrocel 可能具有多种潜在的作用机制，可能导致抗炎、促进血管再生的反应，因此可能在多种罕见和与衰老相关的疾病中具有广泛应用。</p>
<p><strong>关于 Longeveron Inc.</strong> Longeveron 是一家临床阶段生物技术公司，开发再生医学以满足未满足的医疗需求。该公司的主要研究产品是 laromestrocel (LOMECEL-B®)，一种从年轻健康成人捐赠者的骨髓中分离的同种异体间充质干细胞（MSC）疗法产品。Laromestrocel 具有多种潜在的作用机制，包括促进血管、促进再生、抗炎以及组织修复和愈合效果，具有广泛的潜在应用于多种疾病领域。Longeveron 目前正在推进三项管线适应症：左心发育不良综合症（HLHS）、阿尔茨海默病和儿科扩张型心肌病（DCM）。Laromestrocel 开发项目已获得五项重要的 FDA 认证：对于 HLHS 项目 - 孤儿药认证、快速通道认证和罕见儿科疾病认证；对于 AD 项目 - 再生医学先进疗法（RMAT）认证和快速通道认证。有关更多信息，请访问 www.longeveron.com 或在 LinkedIn、X 和 Instagram 上关注 Longeveron。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中某些非历史事实的陈述是根据 1995 年《私人证券诉讼改革法》的安全港条款所作的前瞻性陈述，反映了管理层对未来运营、业绩和经济状况的当前预期、假设和估计，并涉及已知和未知的风险、不确定性以及其他重要因素，这些因素可能导致实际结果、业绩或成就与此处所作陈述的预期、表达或暗示存在重大差异。前瞻性陈述通常可以通过使用 “预期”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“打算”、“着眼于”、“或许”、“在条件下”、“计划”、“潜在”、“预测”、“初步”、“项目”、“看到”、“应该”、“目标”、“将”、“会” 等前瞻性术语，或通过讨论战略或目标或其他未来事件、情况或影响来识别。可能导致实际结果与本发布中任何前瞻性陈述所表达或暗示的结果存在重大差异的因素包括但不限于：我们的现金状况和需要筹集额外资本的需求，我们在获得资本方面可能面临的困难，以及这可能对我们的投资者产生的稀释影响；我们的财务表现，以及继续作为持续经营的能力；我们估计现有现金及现金等价物足以支持未来运营费用和资本支出需求的时间；我们的临床试验能否证明我们产品候选者的安全性和有效性，以及其他积极结果；我们正在进行和未来的临床前研究和临床试验的时间和重点，以及这些研究和试验的数据报告；我们某些产品候选者的市场机会规模，包括我们对患有我们所针对疾病的患者数量的估计；我们在某些适应症上扩大生产和商业化产品候选者的能力；竞争疗法的成功，这些疗法可能已经或将会出现；我们产品候选者的有益特性、安全性、有效性和治疗效果；我们在美国和其他司法管辖区获得和维持产品候选者的监管批准的能力；我们关于进一步开发产品候选者的计划，包括我们可能追求的其他疾病状态或适应症；我们获得或保护知识产权的计划和能力，包括在可用情况下延长现有专利期限的能力，以及我们避免侵犯他人知识产权的能力；需要招聘额外人员以及我们吸引和留住这些人员的能力；以及我们对费用、未来收入、资本需求和额外融资需求的估计。</p>
<p>有关可能影响公司业绩和前瞻性陈述的因素的更多信息已在公司向证券交易委员会提交的文件中披露，包括 Longeveron 截至 2024 年 12 月 31 日的年度报告（Form 10-K），该报告于 2025 年 2 月 28 日向证券交易委员会提交，以及其季度报告（Form 10-Q）和当前报告（Form 8-K）。公司在竞争激烈且快速变化的环境中运营，因此可能会出现新因素，公司管理层无法预测所有可能出现的因素，也无法评估这些因素的影响或任何单一因素或其组合可能导致结果与任何前瞻性陈述中所包含的内容存在重大差异的程度。本新闻稿中包含的前瞻性陈述是基于截至本新闻稿日期可用的信息作出的，固有不确定性，公司不承担任何意图或义务（除法律规定外）更新或修订任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>投资者和媒体联系：</strong></p>
<p>德里克·科尔</p>
<p>投资者关系咨询解决方案</p>
<p>derek.cole@iradvisory.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd016VTJNQ00zTXpJMk1ESXlJekl5TURjd05qQT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd016VTJNQ00zTXpJMk1ESXlJekl5TURjd05qQT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjMyNTY5M2YtYjgzOC00MjBkLWJhNDctMGE2Mzc1OWY2MTg0LTEyMTg2MTMtMjAyNS0xMi0xNy1lbg==/tiny/Longeveron.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjMyNTY5M2YtYjgzOC00MjBkLWJhNDctMGE2Mzc1OWY2MTg0LTEyMTg2MTMtMjAyNS0xMi0xNy1lbg==/tiny/Longeveron.png"/></p>

LGVN

<p>Longeveron Inc. 已获得美国专利，使用其专有的间充质干细胞（MSCs）治疗女性性功能障碍，提高性生活质量。该专利有效期至 2038 年，进一步丰富了 Longeveron 针对与衰老相关疾病的产品组合。该公司计划寻求许可或合作伙伴关系，以开发和商业化这一疗法</p>

<ul>
<li><em>The</em> <em>patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of life</em></li>
<li><em>Female sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy women</em></li>
<li><em>Longeveron anticipates entering into licensing or partnering agreements for the potential development and commercialization of stem cell therapy for this indication</em></li>
</ul>
<div class="lb-trans"><ul>
<li><em>该专利涉及向女性性功能障碍患者施用有效剂量的孤立同种异体间充质干细胞（MSCs）的方法，以提高其性生活质量</em></li>
<li><em>女性性功能障碍是一种极为常见的未满足医疗需求，可能对健康女性的生活质量产生重大影响</em></li>
<li><em>Longeveron 预计将签订许可或合作协议，以开发和商业化针对该适应症的干细胞疗法</em></li>
</ul>
</div><p>MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering administration of the Company’s proprietary mesenchymal stem cells (MSCs) for the treatment of female patients with sexual dysfunction and improvement in sexual quality of life.</p>
<div class="lb-trans"><p>迈阿密，2025 年 12 月 17 日（GLOBE NEWSWIRE）-- Longeveron Inc.（纳斯达克：LGVN），一家开发针对危及生命的罕见儿科和慢性衰老相关疾病的细胞疗法的临床阶段生物技术公司，今天宣布美国专利商标局（USPTO）已授予一项专利，涵盖该公司专有的间充质干细胞（MSCs）用于治疗女性性功能障碍及改善性生活质量的管理。</p>
</div><p>U.S. Patent No. 12,496,316, entitled “Treatment of Sexual Dysfunction and Improvement in Sexual Quality of Life,” provides Longeveron with patent rights in the United States through 2038. Further patent term extension may occur along with regulatory exclusivity extensions.</p>
<div class="lb-trans"><p>美国专利号 12,496,316，标题为 “性功能障碍的治疗及性生活质量的改善”，为 Longeveron 提供了至 2038 年的美国专利权。进一步的专利期限延长可能会与监管独占权延长一起发生。</p>
</div><p>Female sexual dysfunction is an extremely common yet under-researched issue affecting up to 46% of women, with few to no treatment options. Importantly, female sexual dysfunction is increasingly common with advancing age, and affects otherwise healthy individuals. This patent adds to Longeveron’s growing patent portfolio relating to conditions preferentially affecting aging populations.</p>
<div class="lb-trans"><p>女性性功能障碍是一种极为常见但研究不足的问题，影响多达 46% 的女性，治疗选择寥寥无几。重要的是，女性性功能障碍在年龄增长时愈加普遍，影响健康个体。该专利增加了 Longeveron 日益增长的与优先影响老年人群体相关的疾病的专利组合。</p>
</div><p>Longeveron anticipates entering into licensing or partnering agreements for the potential development and commercialization of stem cell therapy for this indication.</p>
<div class="lb-trans"><p>Longeveron 预计将签订许可或合作协议，以开发和商业化针对该适应症的干细胞疗法。</p>
</div><p><strong>About laromestrocel (LOMECEL-B®)</strong></p>
<div class="lb-trans"><p><strong>关于 laromestrocel (LOMECEL-B®)</strong></p>
</div><p>Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to our endogenous biological repair mechanism. MSCs have been shown to perform a number of complex functions in the body, including the formation of new tissue. They also have been shown to respond to sites of injury or disease and secrete bioactive factors that are immunomodulatory and regenerative. We believe that laromestrocel may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.</p>
<div class="lb-trans"><p>Laromestrocel 是一种活细胞产品，由从年轻健康成人捐赠者的骨髓中分离的专门细胞制成。这些专门细胞被称为间充质干细胞（MSCs），对我们内源性生物修复机制至关重要。研究表明，MSCs 在体内执行多种复杂功能，包括新组织的形成。它们还被证明能够响应损伤或疾病的部位，并分泌具有免疫调节和再生作用的生物活性因子。我们相信，laromestrocel 可能具有多种潜在的作用机制，可能导致抗炎、促进血管再生的反应，因此可能在多种罕见和与衰老相关的疾病中具有广泛应用。</p>
</div><p><strong>About Longeveron Inc.</strong> Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.</p>
<div class="lb-trans"><p><strong>关于 Longeveron Inc.</strong> Longeveron 是一家临床阶段生物技术公司，开发再生医学以满足未满足的医疗需求。该公司的主要研究产品是 laromestrocel (LOMECEL-B®)，一种从年轻健康成人捐赠者的骨髓中分离的同种异体间充质干细胞（MSC）疗法产品。Laromestrocel 具有多种潜在的作用机制，包括促进血管、促进再生、抗炎以及组织修复和愈合效果，具有广泛的潜在应用于多种疾病领域。Longeveron 目前正在推进三项管线适应症：左心发育不良综合症（HLHS）、阿尔茨海默病和儿科扩张型心肌病（DCM）。Laromestrocel 开发项目已获得五项重要的 FDA 认证：对于 HLHS 项目 - 孤儿药认证、快速通道认证和罕见儿科疾病认证；对于 AD 项目 - 再生医学先进疗法（RMAT）认证和快速通道认证。有关更多信息，请访问 www.longeveron.com 或在 LinkedIn、X 和 Instagram 上关注 Longeveron。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</p>
<div class="lb-trans"><p>本新闻稿中某些非历史事实的陈述是根据 1995 年《私人证券诉讼改革法》的安全港条款所作的前瞻性陈述，反映了管理层对未来运营、业绩和经济状况的当前预期、假设和估计，并涉及已知和未知的风险、不确定性以及其他重要因素，这些因素可能导致实际结果、业绩或成就与此处所作陈述的预期、表达或暗示存在重大差异。前瞻性陈述通常可以通过使用 “预期”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“打算”、“着眼于”、“或许”、“在条件下”、“计划”、“潜在”、“预测”、“初步”、“项目”、“看到”、“应该”、“目标”、“将”、“会” 等前瞻性术语，或通过讨论战略或目标或其他未来事件、情况或影响来识别。可能导致实际结果与本发布中任何前瞻性陈述所表达或暗示的结果存在重大差异的因素包括但不限于：我们的现金状况和需要筹集额外资本的需求，我们在获得资本方面可能面临的困难，以及这可能对我们的投资者产生的稀释影响；我们的财务表现，以及继续作为持续经营的能力；我们估计现有现金及现金等价物足以支持未来运营费用和资本支出需求的时间；我们的临床试验能否证明我们产品候选者的安全性和有效性，以及其他积极结果；我们正在进行和未来的临床前研究和临床试验的时间和重点，以及这些研究和试验的数据报告；我们某些产品候选者的市场机会规模，包括我们对患有我们所针对疾病的患者数量的估计；我们在某些适应症上扩大生产和商业化产品候选者的能力；竞争疗法的成功，这些疗法可能已经或将会出现；我们产品候选者的有益特性、安全性、有效性和治疗效果；我们在美国和其他司法管辖区获得和维持产品候选者的监管批准的能力；我们关于进一步开发产品候选者的计划，包括我们可能追求的其他疾病状态或适应症；我们获得或保护知识产权的计划和能力，包括在可用情况下延长现有专利期限的能力，以及我们避免侵犯他人知识产权的能力；需要招聘额外人员以及我们吸引和留住这些人员的能力；以及我们对费用、未来收入、资本需求和额外融资需求的估计。</p>
</div><p>Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>有关可能影响公司业绩和前瞻性陈述的因素的更多信息已在公司向证券交易委员会提交的文件中披露，包括 Longeveron 截至 2024 年 12 月 31 日的年度报告（Form 10-K），该报告于 2025 年 2 月 28 日向证券交易委员会提交，以及其季度报告（Form 10-Q）和当前报告（Form 8-K）。公司在竞争激烈且快速变化的环境中运营，因此可能会出现新因素，公司管理层无法预测所有可能出现的因素，也无法评估这些因素的影响或任何单一因素或其组合可能导致结果与任何前瞻性陈述中所包含的内容存在重大差异的程度。本新闻稿中包含的前瞻性陈述是基于截至本新闻稿日期可用的信息作出的，固有不确定性，公司不承担任何意图或义务（除法律规定外）更新或修订任何前瞻性陈述，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Investor and Media Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体联系：</strong></p>
</div><p>Derek Cole</p>
<div class="lb-trans"><p>德里克·科尔</p>
</div><p>Investor Relations Advisory Solutions</p>
<div class="lb-trans"><p>投资者关系咨询解决方案</p>
</div><p>derek.cole@iradvisory.com</p>
<div class="lb-trans"><p>derek.cole@iradvisory.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd016VTJNQ00zTXpJMk1ESXlJekl5TURjd05qQT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMzU2MCM3MzI2MDIyIzIyMDcwNjA="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjMyNTY5M2YtYjgzOC00MjBkLWJhNDctMGE2Mzc1OWY2MTg0LTEyMTg2MTMtMjAyNS0xMi0xNy1lbg==/tiny/Longeveron.png" alt="" original-src="https://ml.globenewswire.com/media/YjMyNTY5M2YtYjgzOC00MjBkLWJhNDctMGE2Mzc1OWY2MTg0LTEyMTg2MTMtMjAyNS0xMi0xNy1lbg==/tiny/Longeveron.png"/></p>

Longeveron 获得美国专利，使用其专有的干细胞疗法治疗女性性功能障碍 | LGVN 股票新闻